Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.43 |
| ▸ | AMD1 | P17707 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19302754 | 0.89 | RXFP1 (0.59) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18571701 | 0.89 | RXFP1 (0.43) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL25949205 | 0.89 | RXFP1 (0.43) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL15390016 | 0.87 | RXFP1 (0.61) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL11759931 | 0.85 | RXFP1 (0.63) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18571944 | 0.84 | RXFP1 (0.39) | RXFP1P2RX3P2RX1P2RX4 | |
| SCHEMBL18571623 | 0.84 | PI4KA (0.62) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18571621 | 0.83 | RXFP1 (0.49) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18512601 | 0.83 | PI4KA (0.54) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5052452 | 0.82 | RXFP1 (0.78) | RXFP1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| EP-4219496-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| EP-3341368-B1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-06 | — | — | EP | disclosed |
| US-20200360416-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-19 | — | — | US | disclosed |
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| WO-2017032840-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | RXFP1 3851/4885PI4KA 2914/4885PI4K2B 3149/4885 |
| US-20200360416-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | RXFP1 3693/4885PI4KA 2834/4885PI4K2B 2839/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | RXFP1 3616/4885PI4KA 2674/4885PI4K2B 2552/4885 |
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | RXFP1 3851/4885PI4KA 2914/4885PI4K2B 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.